These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34711500)

  • 1. Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy.
    Abdel-Azim H; Dave H; Jordan K; Rawlings-Rhea S; Luong A; Wilson AL
    Cytotherapy; 2022 Feb; 24(2):193-204. PubMed ID: 34711500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy.
    Lindgren C; Leinbach A; Annis J; Tanna J; Zhang N; Esensten JH; Hanley PJ
    Cytotherapy; 2021 Feb; 23(2):157-164. PubMed ID: 33189573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy.
    Adams C; Keller M; Michlitsch JG; Aguayo-Hiraldo P; Chen K; Hossain MZ; Davis A; Park JR; Verneris MR; Gardner RA
    Transplant Cell Ther; 2024 May; 30(5):475-487. PubMed ID: 38447751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC).
    Chen HX; Song M; Maecker HT; Gnjatic S; Patton D; Lee JJ; Adam SJ; Moravec R; Liu XS; Cerami E; Lindsay J; Tang M; Hodi FS; Wu CJ; Wistuba II; Al-Atrash G; Bernatchez C; Bendall SC; Hewitt SM; Sharon E; Streicher H; Enos RA; Bowman MD; Tatard-Leitman VM; Sanchez-Espiridion B; Ranasinghe S; Pichavant M; Del Valle DM; Yu J; Janssens S; Peterson-Klaus J; Rowe C; Bongers G; Jenq RR; Chang CC; Abrams JS; Mooney M; Doroshow JH; Harris LN; Thurin M
    Clin Cancer Res; 2021 Sep; 27(18):5038-5048. PubMed ID: 33419780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.
    Fogli LK; Aurigemma R; Sommers CL; Singh A; Bourcier K; Ernstoff MS;
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for immune effector cell therapy collections: a white paper from the American Society for Apheresis.
    Liu HD; Su L; Winters JL; Thibodeaux SR; Park YA; Wu Y; Schwartz J; Zubair AC; Schneiderman J; Gupta GK; Ramakrishnan S; Aqui NA
    Cytotherapy; 2022 Sep; 24(9):916-922. PubMed ID: 35398001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients.
    Nierkens S; Lankester AC; Egeler RM; Bader P; Locatelli F; Pulsipher MA; Bollard CM; Boelens JJ;
    Cytotherapy; 2015 Dec; 17(12):1667-74. PubMed ID: 26589751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Gaspar N; Janeway K; Campbell-Hewson Q; Lawlor ER; Copland C; Karres D; Norga K; Benzaghou F; Weiner S; Weigel B; Weiss AR; Strauss SJ; Smith M; Setty BA; Seibel N; Scobie N; Pappo A; Okpara CE; Nysom K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Lesa G; Knudsen S; Kauh J; Hsieh A; Heenen D; Hawkins DS; Graham A; Garmey E; DuBois SG; Fox E; Donoghue M; de Rojas T; Chung J; Casanova M; Brennan B; Bishop M; Buenger V; Reaman G; Vassal G
    Eur J Cancer; 2022 Sep; 173():71-90. PubMed ID: 35863108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
    Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Rubio MT; Varlet P; Allain V; Ballot C; Cuffel A; Deschamps M; Ferrand C; Foguenne J; Forcade E; Huynh A; Guihot A; Latouche JB; Lemarie C; Martinroche G; Morin F; Nguyen S; Schmit K; Servais S; Simonetta F; Yakoub-Agha I; Caillat Zucman S
    Bull Cancer; 2021 Dec; 108(12S):S53-S64. PubMed ID: 34253335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
    Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
    Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immunotherapy for pediatric solid tumors.
    Hegde M; Moll AJ; Byrd TT; Louis CU; Ahmed N
    Cytotherapy; 2015 Jan; 17(1):3-17. PubMed ID: 25082406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved endpoints for cancer immunotherapy trials.
    Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
    J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry.
    Maryamchik E; Gallagher KME; Preffer FI; Kadauke S; Maus MV
    Cytometry B Clin Cytom; 2020 Jul; 98(4):299-327. PubMed ID: 32352629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.